Polpharma Biologics and Libbs Join Forces to Accelerate Biosimilar Availability for Autoimmune Diseases

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the si...

December 11, 2025 | Thursday | News
SOLVD Health Launches Studies To Validate GLP 1 Patient Stratification Diagnostic Platform

SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, announced the launch of two s...

December 10, 2025 | Wednesday | News
SS Innovations Submits 510(k) Application to FDA for SSi Mantra Surgical Robotic System

SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic...

December 09, 2025 | Tuesday | News
Convergen Secures $10 Million Seed Financing to Advance Next-Generation Targeted Protein Degradation Therapies

Convergen, a biotech company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, announced th...

December 09, 2025 | Tuesday | News
Viatris Secures $815 Million in Strategic Exit From Biocon Biologics Stake

Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Co...

December 08, 2025 | Monday | News
Pfizer Phase 3 BASIS Study Shows HYMPAVZI Delivers 93% Bleed Reduction in Hemophilia With Inhibitors

-Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolesc...

December 08, 2025 | Monday | News
Incyte Announces FDA Breakthrough Therapy Designation for INCA033989 for Essential Thrombocythemia with Type 1 CALR Mutation

Incyte  announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INCA033989, a first-in-class muta...

December 08, 2025 | Monday | News
GE HealthCare and Mayo Clinic Launch GEMINI-RT to Advance Personalized Radiation Therapy

GE HealthCare and Mayo Clinic launch GEMINI-RT, a strategic initiative to personalize radiation therapy by integrating imaging, AI, and patient monit...

December 05, 2025 | Friday | News
AstraZeneca Showcases Broad Advances in Blood Cancer and Rare Disease Care With 65 Presentations at ASH 2025

Investigational T-cell engager, surovatamig, and CAR T-cell therapy, AZD0120, will show potential with initial data across multiple blood cancers New ...

December 05, 2025 | Friday | News
Insulet Receives FDA Clearance for Major Omnipod 5 Algorithm Upgrade Featuring New 100 mg/dL Target Glucose Setting

New 100 mg/dL Target Glucose setting offers more customization and tighter glucose management. Enhanced algorithm helps users remain in Automated Mo...

December 05, 2025 | Friday | News
MUVON Therapeutics Reports Positive Topline Results From Phase 2 SUISSE-MPC2 Trial of MPC-Based Therapy in Female Stress Urinary Incontinence

MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT0553...

December 04, 2025 | Thursday | News
VNA-318 Demonstrates Strong Target Engagement and Safety in First-in-Human Trial

VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation and improve mitochondrial function First-i...

December 03, 2025 | Wednesday | News
Ensoma Launches First-In-Human Study of EN-374 Offering New Hope for People With X-Linked CGD

First ever clinical evaluation of an in vivo HSC-directed gene insertion therapy aims to restore immune function for people living with X-linked chroni...

December 02, 2025 | Tuesday | News
InnoCare Pharma Doses First Patient in Global Phase II Trial of Soficitinib for Prurigo Nodularis

InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced tha...

December 01, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close